The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Characterization of Distinct Immunophenotypes across Pediatric Brain Tumor Types
Open accessAbstract
Despite increasing evidence that antitumor immune control exists in the pediatric brain, these findings have yet to be exploited successfully in the clinic. A barrier to development of immunotherapeutic strategies in pediatric brain tumors is that the immunophenotype of these tumors’ microenvironment has not been defined. To address this, the current study used multicolor FACS of disaggregated tumor to systematically characterize the frequency and phenotype of infiltrating immune cells in the most common pediatric brain tumor types. The initial study cohort consisted of 7 pilocytic astrocytoma (PA), 19 ependymoma (EPN), 5 glioblastoma (GBM), 6 medulloblastoma (MED), and 5 nontumor brain (NT) control samples obtained from epilepsy surgery. Immune cell types analyzed included both myeloid and T cell lineages and respective markers of activated or suppressed functional phenotypes. Immune parameters that distinguished each of the tumor types were identified. PA and EPN demonstrated significantly higher infiltrating myeloid and lymphoid cells compared with GBM, MED, or NT. Additionally, PA and EPN conveyed a comparatively activated/classically activated myeloid cell–skewed functional phenotype denoted in particular by HLA-DR and CD64 expression. In contrast, GBM and MED contained progressively fewer infiltrating leukocytes and more muted functional phenotypes similar to that of NT. These findings were recapitulated using whole tumor expression of corresponding immune marker genes in a large gene expression microarray cohort of pediatric brain tumors. The results of this cross-tumor comparative analysis demonstrate that different pediatric brain tumor types exhibit distinct immunophenotypes, implying that specific immunotherapeutic approaches may be most effective for each tumor type.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Mosmann, T. R., Cherwinski, H., Bond, M. W., Giedlin, M. A., & Coffman, R. L. (1986) · The Journal of Immunology · doi:10.4049/jimmunol.136.7.2348 · Cited by 7,506
Alternative activation of macrophages
Gordon, S. (2003) · Nature Reviews Immunology · doi:10.1038/nri978 · Cited by 6,189
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768 · cited 1×
“Ab-dependent cell-mediated cytotoxicity is considered to be the dominant mechanism of the in vivo activity of Abs against tumors and is particularly dependent on engagement of Ab with FcgRs expressed by immune effector cells (32).”
BackgroundThe many faces of macrophage activation
Mosser, D. M. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0602325 · Cited by 1,902
A Model-Based Background Adjustment for Oligonucleotide Expression Arrays
Wu, Z., Irizarry, R. A., Gentleman, R., Martinez-Murillo, F., & Spencer, F. (2004) · Journal of the American Statistical Association · doi:10.1198/016214504000000683 · Cited by 1,716
Dudley, M. E., Wunderlich, J. R., Yang, J. C., Sherry, R. M., Topalian, S. L., Restifo, N. P., Royal, R. E., Kammula, U., White, D. E., Mavroukakis, S. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.240 · Cited by 1,639
Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes
Agata, Y., Kawasaki, A., Nishimura, H., Ishida, Y., Tsubat, T., Yagita, H., & Honjo, T. (1996) · International Immunology · doi:10.1093/intimm/8.5.765 · Cited by 1,589
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
Parsa, A. T., Waldron, J. S., Panner, A., Crane, C. A., Parney, I. F., Barry, J. J., Cachola, K. E., Murray, J. C., Tihan, T., Jensen, M. C., et al. (2007) · Nature Medicine · doi:10.1038/nm1517 · Cited by 1,344
Zeng, J., See, A. P., Phallen, J., Jackson, C. M., Belcaid, Z., Ruzevick, J., Durham, N., Meyer, C., Harris, T. J., Albesiano, E., et al. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.12.025 · Cited by 889
Possible involvement of the M2 anti‐inflammatory macrophage phenotype in growth of human gliomas
Komohara, Y., Ohnishi, K., Kuratsu, J., & Takeya, M. (2008) · The Journal of Pathology · doi:10.1002/path.2370 · Cited by 738
T-helper-1-cell cytokines drive cancer into senescence
Braumüller, H., Wieder, T., Brenner, E., Aßmann, S., Hahn, M., Alkhaled, M., Schilbach, K., Essmann, F., Kneilling, M., Griessinger, C., et al. (2013) · Nature · doi:10.1038/nature11824 · Cited by 720
De Monte, L., Reni, M., Tassi, E., Clavenna, D., Papa, I., Recalde, H., Braga, M., Di Carlo, V., Doglioni, C., & Protti, M. P. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101876 · Cited by 695
Edin, S., Wikberg, M. L., Dahlin, A. M., Rutegård, J., Öberg, Å., Oldenborg, P.-A., & Palmqvist, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047045 · Cited by 454
Identification and manipulation of tumor associated macrophages in human cancers
Heusinkveld, M., & van der Burg, S. H. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-216 · Cited by 435
Systematic validation of specific phenotypic markers for in vitro polarized human macrophages
Ambarus, C. A., Krausz, S., van Eijk, M., Hamann, J., Radstake, T. R. D. J., Reedquist, K. A., Tak, P. P., & Baeten, D. L. P. (2012) · Journal of Immunological Methods · doi:10.1016/j.jim.2011.10.013 · Cited by 411
de Martin, R., Haendler, B., Hofer-Warbinek, R., Gaugitsch, H., Wrann, M., Schlüsener, H., Seifert, J. M., Bodmer, S., Fontana, A., & Hofer, E. (1987) · The EMBO Journal · doi:10.1002/j.1460-2075.1987.tb02700.x · Cited by 384
Rodrigues, J. C., Gonzalez, G. C., Zhang, L., Ibrahim, G., Kelly, J. J., Gustafson, M. P., Lin, Y., Dietz, A. B., Forsyth, P. A., Yong, V. W., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop023 · Cited by 244
Diederichsen, A. C. P., v. B. Hjelmborg, J., Christensen, P. B., Zeuthen, J., & Fenger, C. (2003) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-003-0388-5 · Cited by 237
Sippel, T. R., White, J., Nag, K., Tsvankin, V., Klaassen, M., Kleinschmidt-DeMasters, B. K., & Waziri, A. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1107 · Cited by 195
Self-citationCaruso, D. A., Orme, L. M., Neale, A. M., Radcliff, F. J., Amor, G. M., Maixner, W., Downie, P., Hassall, T. E., Tang, M. L. K., & Ashley, D. M. (2004) · Neuro-Oncology · doi:10.1215/s1152851703000668 · Cited by 165
Human Glioma-derived Interleukin-10 Inhibits Antitumor Immune Responses In Vitro
Hishii, M., Nitta, T., Ishida, H., Ebato, M., Kurosu, A., Yagita, H., Sato, K., & Okumura, K. (1995) · Neurosurgery · doi:10.1227/00006123-199512000-00016 · Cited by 160
Yang, I., Han, S. J., Sughrue, M. E., Tihan, T., & Parsa, A. T. (2011) · Journal of neurosurgery · doi:10.3171/2011.4.jns101172 · Cited by 146
Adjuvant dendritic cell‐based tumour vaccination for children with malignant brain tumours
Ardon, H., Vleeschouwer, S. D., Calenbergh, F. V., Claes, L., Kramm, C. M., Rutkowski, S., Wolff, J. E. A., & Gool, S. W. V. (2009) · Pediatric Blood & Cancer · doi:10.1002/pbc.22319 · Cited by 144
Choi, C., Xu, X., Oh, J., Lee, S. J., Gillespie, G. Y., Park, H., Jo, H., & Benveniste, E. N. (2001) · PubMed · Cited by 96
Donson, A. M., Birks, D. K., Schittone, S. A., Kleinschmidt-DeMasters, B. K., Sun, D. Y., Hemenway, M. S., Handler, M. H., Waziri, A. E., Wang, M., & Foreman, N. K. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103373 · Cited by 69
Self-citationAltered Expression of Immune Defense Genes in Pilocytic Astrocytomas
Huang, H., Hara, A., Homma, T., Yonekawa, Y., & Ohgaki, H. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/01.jnen.0000183345.19447.8e · Cited by 67
Immune Gene and Cell Enrichment Is Associated with a Good Prognosis in Ependymoma
Donson, A. M., Birks, D. K., Barton, V. N., Wei, Q., Kleinschmidt-DeMasters, B. K., Handler, M. H., Waziri, A. E., Wang, M., & Foreman, N. K. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0902811 · Cited by 63
Self-citationBirks, D. K., Donson, A. M., Patel, P. R., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor140 · Cited by 59
Self-citationZahuczky, G., Kristóf, E., Majai, G. E., & Fésüs, L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021349 · Cited by 57
Estecha, A., Aguilera‐Montilla, N., Sánchez‐Mateos, P., & Puig‐Kröger, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033313 · Cited by 39
TH1 predominance is associated with improved survival in pediatric medulloblastoma patients
Wiegering, V. A., Eyrich, M. K., Rutkowski, S., Wölfl, M., Schlegel, P. G., & Winkler, B. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-0981-y · Cited by 22
Cited by
Northcott, P. A., Robinson, G. W., Kratz, C. P., Mabbott, D. J., Pomeroy, S. L., Clifford, S. C., Rutkowski, S., Ellison, D. W., Malkin, D., Taylor, M. D., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0063-6 · Cited by 649
Subgroup-specific immune and stromal microenvironment in medulloblastoma
Bockmayr, M., Mohme, M., Klauschen, F., Winkler, B., Budczies, J., Rutkowski, S., & Schüller, U. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1462430 · Cited by 121
Dunkel, I. J., Doz, F., Foreman, N. K., Hargrave, D., Lassaletta, A., André, N., Hansford, J. R., Hassall, T., Eyrich, M., Gururangan, S., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad031 · Cited by 73
Self-citation
Metadata
- Authors
- Griesinger, A. M., Birks, D. K., Donson, A. M., Amani, V., Hoffman, L. M., Waziri, A., Wang, M., Handler, M. H., & Foreman, N. K.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-11-01
- Volume
- 191
- Issue
- 9
- Pages
- 4880-4888
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2138541072
- Cited by
- 260
- References
- 36
- FWCI
- 2.66
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.